Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: Updated meta-analysis

BMJ Open

Volumn 4, Issue 2, 2014, Pages

  Cui, Ai ^a   Jin, Xiao Guang ^a   Zhai, Kan ^b   Tong, Zhao Hui ^a   Shi, Huan Zhong ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Institute of Respiratory Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MEGAKARYOCYTE POTENTIATING FACTOR; MESOTHELIN; SOLUBLE MESOTHELIN RELATED PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MEMBRANE PROTEIN;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; META ANALYSIS; PLEURA FLUID; PLEURA MESOTHELIOMA; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TASK PERFORMANCE; BLOOD; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS;

BIOMARKERS, TUMOR; GPI-LINKED PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS;

EID: 84896826988     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004145     Document Type: Article

References (57)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408. (Pubitemid 41073959)
2. West SD, Lee YC. Management of malignant pleural mesothelioma. Clin Chest Med 2006;27:335-54. (Pubitemid 43729178)
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. (Pubitemid 46606305)
4. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-9.
5. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479-95.
6. van der Bij S, Schaake E, Koffijberg H, et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 2011;104:1325-33.
7. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136 -40.
8. Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci 2008;99:590-4. (Pubitemid 351228578)
9. Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 2006;56:649-54. (Pubitemid 44570013)
10. Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J 2013;41:706-15.
11. Luo L, Shi HZ, Liang QL, et al. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med 2010;104:149-56.
12. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012;30:1541 -9.
13. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-4. (Pubitemid 36110721)
14. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
15. Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002;2:9.
16. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-316. (Pubitemid 23230833)
17. Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 2008;63:35-41.
18. Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 1995;48:119-30.
19. Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med 1998;122:675 -86.
20. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
21. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-16. (Pubitemid 37443528)
22. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006;12:4225-31.
23. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60. (Pubitemid 43726897)
24. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666-72. (Pubitemid 46580236)
25. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239 -46.
26. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-81. (Pubitemid 47502073)
27. Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 2007;45:634-8. (Pubitemid 46709735)
28. Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev 2008;17:163-70. (Pubitemid 351196287)
29. Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 2008;14:1431-7. (Pubitemid 351413926)
30. Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 2008;62:45-54.
31. van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2008;59:350-4. (Pubitemid 351335105)
32. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008;3:851-7.
33. Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008; 3:1317-24.
34. Davies HE, Sadler RS, Bielsa S, et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009;180:437-44.
35. Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009;18:646-50.
36. Fujimoto N, Gemba K, Asano M, et al. Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma. Exp Ther Med 2010;1:313-17.
37. Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620-5.
38. Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma - which is best? Lung Cancer 2011;74:55-60.
39. Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011;6:1587-93.
40. Dipalma N, Luisi V, Di Serio F, et al. Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide. Int J Biol Markers 2011;26:160-5.
41. Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 2011;49:1721-6.
42. Ashour WM, Amin H, Sabri IM, et al. Combined blood and pleural levels of mesothelin and osteopontin for the diagnosis of malignant pleural mesothelioma. Egyptian J Chest Dis Tuberc 2012;61: 121-8.
43. Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. J Thorac Oncol 2012;7:883-9.
44. Amany FM, Mohamed NA, El-Ghamry R, et al. Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis. Egyptian J Chest Dis Tuberc 2013;62:115-20.
45. Canessa PA, Franceschini MC, Ferro P, et al. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest 2013;31:43-50.
46. Creaney J, Sneddon S, Dick IM, et al. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. Dis Markers 2013;35:119-27.
47. Ferro P, Canessa PA, Battolla E, et al. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. Anticancer Res 2013;33:2707-13.
48. Filiberti R, Parodi S, Libener R, et al. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA. Med Oncol 2013;30:543.
49. Hooper CE, Morley AJ, Virgo P, et al. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. Eur Respir J 2013;41:18-24.
50. Bayram M, Dongel I, Akbaş A, et al. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Lung . Published Online First: 30 Oct 2013. doi: 10.1007/s00408-013-9526-9
51. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317-31.
52. Cristaudo A, Bonotti A, Simonini S, et al. Soluble markers for diagnosis of malignant pleural mesothelioma. Biomark Med 2011;5:261-73.
53. Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care. Meta-analysis in context. London: BMJ Publishing Group, 2001:248-82.
54. Jaeschke R, Guyatt G, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, eds. Users' guides to the medical literature. A manual for evidence-based clinical practice. Chicago, IL: AMA Press, 2002;121-40.
55. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-72. (Pubitemid 350265805)
56. Grigoriu BD, Chahine B, Vachani A, et al . Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009;179:950-4.
57. Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related peptide and osteopontin as markers of response to treatment in malignant mesothelioma. J Clin Oncol 2010;28:3316-22.